By having the right people at the right time, there's no limit to achieve.
By having the right people at the right time, there's no limit to achieve.

Then several cell and animal studies were carried out by implementing a research plan and attracting research grants.

2016

2019

In 2016, after working at Fasa University of Medical Sciences in Iran and participating in a scientific research conference, Dr. Nahid Mortazavi learned about medicinal plants' effects in treating skin diseases.
From that moment, she sought the answer to the question of how to use the properties of herbal products to improve the symptoms of eczema. She formed a group of colleagues to investigate this matter. After two years of research and examining medicinal plants, they found more than 100 effective plants. During this period, with the cooperation of bioinformatics experts and the identification of effective molecules in the disease process, the necessary predictions were made using artificial intelligence. Finally, suitable natural plants to improve the symptoms of various diseases were selected from the collection of primary plants.

After the MTA incubator announced its support for the commercialization of the idea in Canada, a limited liability company was registered in Manitoba in July 2021. After that, the follow-up of research works was done more quickly.

Executive Summary

2020

According to the valuable results obtained in pre-clinical studies, a pilot clinical (human) trial study was conducted in 2020 (HMX202001). After observing the extraordinary results in reducing the symptoms of diseases, especially the treatment of eczema, Naheed decided to establish a company with his colleagues to produce and supply natural herbal products for the treatment of eczema in Canada.

2021

2022

Cell and animal studies to find new treatment for Psoriasis(HMX202202) .

2024

Conduct new clinical trial for Atopic dermatitis (HMX202001)
​​​​​​​

Conduct new clinical trial for Psoriasis (HMX202202)
Cell and animal studies to find new treatment for Psoriasis and Cutaneous leishmaniasis (CL)